- 27 October 2025
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 87 (5) , 28-35
Abstract
One of the main prognostic factors for meningioma recurrence is histological diagnosis with an assessment of tumor grade. Despite this, there are no clear microscopic criteria for recurrence prognosis in benign forms, and there is no common understanding of meningioma recurrence and continued growth clinical management. Objective. To evaluate neuroimaging, microscopic features and proliferative activity in meningioma recurrence and continued growth. Material and methods. Histological and immunohistochemical studies of tumor biopsies were performed in 16 patients with tumor progression who underwent surgery for recurrence and continued growth of intracranial meningiomas; the comparison group included 10 patients with newly diagnosed intracranial meningioma. All patients were performed pathomorphological and radiological examination assessment. Results. The average tumor volume in the meningioma progression group was 48.88±14.32 cm3; the average tumor volume was higher in the primary surgical treatment group — 51.51±14.48 cm3. Recurrent tumors were characterized by more pronounced cellular and tissue atypia, patterns of infiltrative growth with the involvement of large vessels. The meningioma proliferative activity, assessed by Ki-67(max) expression, was higher in the group with meningioma progression and amounted to 9.71±2.5%. Significant differences in the Ki-67 expression were noted by tumor localization, grade, and brain invasion (p<0.05) in the meningioma recurrence and continued growth group. Conclusion. Recurrent meningiomas are represented by different grade tumors, including benign typical meningioma (grade 1), which indicates the need for greater attention and patient follow-up with this pathology. There are differences in terms of grade progression and locally destructive growth in meningioma recurrence and continued growth. This indicates a more pronounced biological tumor aggression. The Ki-67 expression is an important prognostic factor in meningioma progression group.Keywords
This publication has 11 references indexed in Scilit:
- Topographic Patterns of Intracranial Meningioma Recurrences—Systematic Review with Clinical ImplicationCancers, 2024
- NCCN CNS tumor guidelines update for 2023Neuro-Oncology, 2023
- Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системыMalignant tumours, 2022
- The Biomarker Ki-67: Promise, Potential, and Problems in Breast CancerApplied Immunohistochemistry & Molecular Morphology, 2022
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- EANO guideline on the diagnosis and management of meningiomasNeuro-Oncology, 2021
- Recurrence/Regrowth in Grade I Meningioma: How to Predict?Frontiers in Oncology, 2020
- Meningioma Tumor Microenvironment2020
- Relationship between tumor location, size, and WHO grade in meningiomaNeurosurgical Focus, 2018
- Peritumoral edema and prognosis in intracranial meningioma surgeryJournal of Clinical Neuroscience, 2008